|
|
Investor Relations
Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products for the treatment of diseases and disorders in the central nervous system therapeutic area. Somaxon's lead product candidate is Silenor® (doxepin) for the treatment of insomnia.
Latest News
Jan 27, 2010
Somaxon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference (pdf)
Jan 21, 2010
SOMAXON PROVIDES UPDATE ON NEW DRUG APPLICATION FOR SILENOR® FOR THE TREATMENT OF INSOMNIA (pdf)
Webcasts
Feb 8, 2010 at 9:30 AM ET
12th Annual BIO CEO & Investor Conference
|
| Stock Quote |
SOMX(Common Stock)
Last Trade $2.68
Change  0.29
Exchange NASDAQ
Volume 2,407,900
02/08/10 3:59 PM ET
Minimum 20 Minute Delay.
Refresh Quote.
|
Annual Reports
|
